Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Myung Ju Ahn, Ji Youn Han, Ki Hyeong Lee, Sang We Kim, Dong Wan Kim, Yun Gyoo Lee, Eun Kyung Cho, Joo Hang Kim, Gyeong Won Lee, Jong Seok Lee, Young Joo Min, Jin Soo Kim, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong Mu Sun, Heung Tae Kim, Dae Ho Lee, Sohee KimByoung Chul Cho

Research output: Contribution to journalArticle

5 Scopus citations

Fingerprint Dive into the research topics of 'Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences